
Syed Maaz Abdullah Mbbs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4310901/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Aging and therapyâ€related hypogammaglobulinemia causing pneumonia: An overlooked curable entity in the chaotic COVIDâ€19 pandemic. Journal of Medical Virology, 2021, 93, 202-203.	2.5	2
2	Examining and investigating the impact of demographic characteristics and chronic diseases on mortality of COVID-19: Retrospective study. PLoS ONE, 2021, 16, e0257131.	1.1	11
3	<p>A Systematic Review of Transfusion-Transmissible Infections Among Blood Donors and Associated Safety Challenges in Pakistan</p> . Journal of Blood Medicine, 2020, Volume 11, 405-420.	0.7	11
4	COVID-19 and the ABO blood group connection. Transfusion and Apheresis Science, 2020, 59, 102838.	0.5	35
5	Efficacy of Venetoclax Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2020, 136, 39-40.	0.6	2
6	Efficacy of High Dose Chemotherapy with Autologous Transplantation for Primary CNS Lymphoma Treatment. Blood, 2020, 136, 3-4.	0.6	0
7	Role of Hypomethylating Agents in Accelerated and Blast Phase of Philadelphia Negative Myeloproliferative Neoplasms: A Systematic Review. Blood, 2020, 136, 20-21.	0.6	0
8	A Systematic Review on Efficacy and Safety of Bortezomib Based Regimens for Treatment of Waldensterom Macroglobulinemia. Blood, 2020, 136, 12-12.	0.6	0
9	Efficacy of Ixazomib and Bortezomib with Lenalidomide Combination Regimens for Multiple Myeloma: A Systematic Review. Blood, 2020, 136, 40-41.	0.6	1
10	A Systematic Review of Daratumumab Based Four Drug Regimen for Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials. Blood, 2020, 136, 36-37.	0.6	1
11	A Systematic Review of High Dose Chemotherapy with Autologous Transplantation in Secondary CNS Lymphoma. Blood, 2020, 136, 14-14.	0.6	0
12	Efficacy of Chemotherapeutic Regimens for Mantle Cell Lymphoma: A Systematic Review of Phase III Trials. Blood, 2020, 136, 6-7.	0.6	0
13	Safety and Efficacy of Purine Analogs for Treatment of Waldenstrom Macroglobulinemia. Blood, 2020, 136, 9-10.	0.6	0
14	Post-Transplant Lymphoproliferative Disorder after Renal Transplant in the Pediatric Population: A Systematic Review. Blood, 2020, 136, 35-36.	0.6	1
15	Systematic Review of Phase III Trials of Daratumumab Based Regimens in Relapsed Refractory Multiple Myeloma. Blood, 2020, 136, 4-5.	0.6	0
16	Safety and Adverse Reactions of CAR T Therapy for the Treatment of Multiple Myeloma: A Systematic Review. Blood, 2020, 136, 6-7.	0.6	1
17	Post-Transplant Lymphoproliferative Disorder after Liver Transplant: A Systematic Review. Blood, 2020, 136, 34-35.	0.6	0
18	Rituximab and Cyclophosphamide Based Regimens for Treatment of Waldensterom Macroglobulemia, Lessons from Clinical Literature: A Systemic Review, Blood, 2020, 136, 10-11	0.6	1

#	Article	IF	CITATIONS
19	Efficacy of Isatuximab on Surrogate Endpoints in Multiple Myeloma; A Systematic Review. Blood, 2020, 136, 34-34.	0.6	0
20	A Systemic Review on Efficacy of Ibrutinib-Based Regimens for the Treatment of Waldenstrom Macroglobulinemia. Blood, 2020, 136, 8-9.	0.6	1
21	Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review. Blood, 2020, 136, 29-30.	0.6	0
22	Post-Transplant Lymphoproliferative Disorder after Heart Transplant in the Pediatric Population: A Systematic Review. Blood, 2020, 136, 37-37.	0.6	0
23	Efficacy and Safety of Amlodipine in Preventing Myocardial Iron Overload in Patients with Transfusion-Dependent Thalassemia Major : A Systematic Review and Meta-Analysis. Blood, 2020, 136, 48-49.	0.6	1
24	Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review. Blood, 2020, 136, 31-32.	0.6	0
25	Defining Quality Though a Collaborative Process for Multiple Myeloma Care. Blood, 2020, 136, 22-23.	0.6	0
26	Treatment Options for Newly Diagnosed Frail and Transplant-Ineligible Patients with Multiple Myeloma: A Systematic Review. Blood, 2020, 136, 18-19.	0.6	0
27	The Comparison of Novel Oral Anticoagulants with Conventional Anticoagulants in the Treatment of Cancer-Associated Thrombosis: A Systemic Review. Blood, 2020, 136, 15-16.	0.6	0
28	Comparing the Efficacy of Cyclophosphamide Versus Lenalidomide in Combination with Bortezomib for Newly Diagnosed Multiple Myeloma Treatment: A Systematic Review. Blood, 2020, 136, 42-42.	0.6	0
29	Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies. Blood, 2019, 134, 4442-4442.	0.6	4
30	Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review. Blood, 2019, 134, 5597-5597.	0.6	1
31	Prevalence of hepatitis C virus among healthy donors at a large Teaching Hospital in Lahore, Pakistan: A cause of concern for health policy makers The Professional Medical Journal, 2019, 26, 1413-1418.	0.0	1
32	Comparative Efficacy and Safety of Once Versus Twice Weekly Carfilzomib Based Therapies in Relapsed Refractory Multiple Myeloma- a Systematic Review. Blood, 2019, 134, 3150-3150.	0.6	0
33	A Systematic Review on Efficacy and Safety of Lenalidomide Based Regimens for Treatment of Newly Diagnosed Amyloidosis. Blood, 2019, 134, 5584-5584.	0.6	Ο
34	Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review. Blood, 2019, 134, 5589-5589.	0.6	0
35	Melphalan Based Regimens for Treatment of Newly Diagnosed Amyloidosis, Lessons from Clinical Literature: A Systematic Review. Blood, 2019, 134, 5561-5561.	0.6	0
36	Efficacy and Toxicity of Lenalidomide for Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. Blood, 2019, 134, 5488-5488.	0.6	0

#	Article	IF	CITATIONS
37	Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. Blood, 2019, 134, 5588-5588.	0.6	ο
38	Efficacy of sofosbuvir in interferon treated patients of hepatitis C infected with 3a genotype The Professional Medical Journal, 2019, 26, 1606-1612.	0.0	0